§07 · Questions
PT-141 Questions, Answered From the Record
Direct answers to the most-asked PT-141 questions, each one sourced — no hype, no sales.
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the developmental code name; bremelanotide is the international nonproprietary name (INN) for the same molecule — a synthetic cyclic heptapeptide and melanocortin receptor agonist [1][10]. The approved-drug form carries the name bremelanotide; "PT-141" is most often how the research-chemical form is labeled.
What is bremelanotide?
Bremelanotide is a synthetic analogue of alpha-MSH that activates central melanocortin receptors, chiefly MC4R, in the hypothalamus and limbic system [1]. It is the FDA-approved drug (NDA 210557, 2019) for HSDD in premenopausal women, the same molecule sold elsewhere under the code name PT-141 [7][10].
What is the approved bremelanotide dose?
The approved dose is 1.75 mg injected subcutaneously, as needed, at least 45 minutes before anticipated activity, with a maximum of one dose per 24 hours and no more than eight doses per month [7]. This is the labeled dose for the approved HSDD indication in premenopausal women — not a recommendation for any individual.
Is PT-141 approved for men?
No. PT-141 is not FDA-approved for men. Early studies did test it in men with erectile dysfunction and found dose-dependent erectile activity consistent with a central mechanism [1], but that never produced an approval. The only approved indication is HSDD in premenopausal women; any use in men is off-label [10].
Is PT-141 FDA-approved?
Yes, for one narrow use. The active drug bremelanotide was FDA-approved on June 21, 2019 (NDA 210557) for acquired, generalized HSDD in premenopausal women [7][10]. It is not approved for men, postmenopausal women, erectile dysfunction, or performance. The separate "PT-141 research chemical" is not the approved drug [10].
Is PT-141 legal in the US?
It depends which form you mean. Bremelanotide is a legal prescription pharmaceutical for its approved HSDD indication [7]. The "PT-141 research chemical" is sold for laboratory use only, is not the approved drug, and sits outside the pharmaceutical framework with no oversight of identity, purity, or concentration [10]. This site does not advise on personal legal status.
Can you get PT-141 through telehealth?
This site is editorial and does not facilitate access or prescriptions. As a matter of record, bremelanotide is a prescription drug for its approved indication, and prescribing decisions are made by licensed clinicians [7]. Material marketed as "research chemical" is a different, unregulated product and not the approved drug [10].
What is PT-141?
PT-141 is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist, switching on MC4R and MC3R receptors concentrated in the brain [1]. As the approved drug bremelanotide, it treats HSDD in premenopausal women; it is a central-acting compound, not a blood-flow drug [7][10].
What is PT-141 peptide?
The PT-141 peptide is a seven-amino-acid ring-shaped molecule, a lab-made analogue of the natural peptide alpha-MSH [1]. The cyclic structure makes it more stable than linear melanocortin peptides. It acts in the central nervous system on melanocortin receptors that help govern sexual desire [1].
What does the PT-141 peptide do?
PT-141 activates central melanocortin receptors, mainly MC4R in the hypothalamus, engaging dopamine pathways tied to sexual desire and arousal [1]. In trials it raised desire and lowered desire-related distress in premenopausal women with HSDD [3]. It works through the brain, not through vascular blood flow [1].
What is PT-141 used for?
As the approved drug bremelanotide, PT-141 is used for acquired, generalized HSDD — low sexual desire causing distress — in premenopausal women [7][10]. Other uses people ask about (men, erectile dysfunction, postmenopausal women, performance) are off-label and were not part of the FDA approval [10].
How does PT-141 work?
PT-141 activates melanocortin receptors, chiefly MC4R, in hypothalamic circuits such as the medial preoptic area, engaging dopamine signaling linked to sexual motivation [1]. A brain-imaging study showed MC4R activation altered processing of erotic cues and raised desire for up to 24 hours [5]. It acts centrally, unlike peripherally acting erection drugs [1].
What receptors does PT-141 act on?
PT-141 is an agonist at melanocortin receptors, primarily MC4R and secondarily MC3R, both concentrated in the central nervous system [1]. MC4R agonism in hypothalamic appetite circuits also underlies the caloric-intake effects seen at high experimental dosing, and peripheral MC1R activation underlies hyperpigmentation with frequent dosing [11].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on melanocortin receptors in hypothalamic and limbic circuits, engaging the neural circuitry of sexual motivation [1]. This is the key contrast with PDE-5 inhibitors, which act peripherally on vascular smooth muscle to affect blood flow. PT-141 does not act on vascular smooth muscle [1].
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that switches on melanocortin receptors — a family of five G-protein-coupled receptors (MC1R-MC5R) that respond to peptides like alpha-MSH. PT-141 is an agonist at the central subtypes MC3R and MC4R, which is how it engages sexual-desire circuitry [1].
Does PT-141 increase testosterone?
No. PT-141 does not act through the hormone axis that controls testosterone and does not directly raise it [10]. This is a common misconception. It works on central melanocortin receptors that influence sexual desire, a mechanism entirely separate from testosterone production [1][10].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on the smooth muscle of blood vessels to improve erectile blood flow. PT-141 acts centrally, on melanocortin receptors in the brain that govern sexual motivation [1]. They target different parts of the sexual-response pathway — one vascular, one neural — and are mechanistically distinct [1].
What is the PT-141 dosage?
The approved bremelanotide dosage is 1.75 mg subcutaneous, as needed, with a maximum of one dose per 24 hours and no more than eight per month, for HSDD in premenopausal women [7]. This is documentation of the label, not a recommendation. No individual dose is advised on this site.
How much PT-141 should I take?
This site does not recommend a dose for any individual. As a matter of record, the FDA-approved label for bremelanotide specifies 1.75 mg subcutaneous as needed, capped at one dose per 24 hours and eight per month, for the approved HSDD indication in premenopausal women [7]. Dosing decisions belong to a licensed clinician.
How much PT-141 to inject?
The approved label specifies a 1.75 mg subcutaneous dose for bremelanotide, with strict frequency limits (max one per 24 hours, eight per month) [7]. That is the documented label figure for the approved indication, not guidance for any individual. This site provides no injection instructions and no personal dose.
What is the PT-141 dosage for women?
The FDA-reviewed dose for women is 1.75 mg subcutaneous, as needed, studied in premenopausal women with HSDD [7]. Phase 2 dose-finding in women evaluated 0.75, 1.25, and 1.75 mg before 1.75 mg was approved [10]. The female evidence base also includes preclinical solicitational-behavior findings in rats [2].
How do you reconstitute PT-141?
This site does not provide reconstitution or preparation instructions. As documentation: the approved bremelanotide product is a 1.75 mg subcutaneous injection, with administration handled per its label and by clinicians [7]. The separate "research chemical" form is unregulated, with no verified identity, purity, or concentration, so no preparation guidance is offered here [10].